GPN Vaccines
PrivateLast Round
Private Placement
Nov 2, 2026
Est. Valuation
$300M
Total Funding Raised
$25.2M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
GPN Vaccines operates in Healthcare & Life Sciences and is based in Canberra. Its latest recorded funding round was a Private Placement round in November 2026.
GPN Vaccines is a biotechnology company that develops innovative vaccines designed to provide broad-spectrum protection against Streptococcus pneumoniae and other bacterial pathogens.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GPN Vaccines Comparables
Compare GPN Vaccines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ReNewVax Ltd. | 84% | |
| Vaxcyte | 80% | |
| Inventprise | 80% |
For institutional investors. Book with your work email.
GPN Vaccines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Nov 2, 2026 | ||||
| Series B Extension | Jun 5, 2024 | ||||
| Grant | May 7, 2024 | ||||
| Series A Extension | Jan 31, 2023 | ||||
| Series A Extension | Jun 30, 2020 | ||||
Grant | Apr 10, 2020 |
For institutional investors. Book with your work email.
GPN Vaccines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forepont Capital Partners | Series A Extension, Series B Extension |
| CUREator | Grant |
| South Australian Early Commercialisation Fund | Grant |
| Astute Ventures | Series A Extension |
| Shearwater Capital | Series B Extension |
| Kern Capital | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 2, 2026
$10M raised in a private placement round.
- Apr 23, 2026
Grew 18% QoQ, from 28 to 33 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 2, 2026
GPN Vaccines closes a $10M private placement financing with new and existing investors on Nov 2nd '26 in New York and Australia to support Phase 2-enabling activities for its Gamma-PN vaccine candidate.
- attends_eventSep 28, 2026
GPN Vaccines will present progress across its vaccine portfolio at the World Vaccine Congress Europe on Oct 19th-21st '26 in Netherlands.
- attends_eventSep 28, 2026
GPN Vaccines will present progress across its vaccine portfolio at the International Society for Vaccines (ISV) Annual Congress in Antwerp, Belgium, on Oct 12-14, 2026.
For institutional investors. Book with your work email.
GPN Vaccines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GPN Vaccines's valuation, stock price, and market status.
Is GPN Vaccines a public or private company?
GPN Vaccines is a private company.
What is the current stock price of GPN Vaccines?
GPN Vaccines is a private company, so its shares have no public market price. Caplight tracks GPN Vaccines's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GPN Vaccines worth (valuation)?
GPN Vaccines's valuation is estimated at $300.0M based on funding round data.
Can I buy GPN Vaccines stock?
GPN Vaccines shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GPN Vaccines's last funding round?
GPN Vaccines's most recent funding round was Private Placement on November 2, 2026.
Who are the main investors in GPN Vaccines?
Key investors in GPN Vaccines include Forepont Capital Partners.
Will GPN Vaccines IPO soon?
No public IPO plans have been announced for GPN Vaccines.
How can I track GPN Vaccines secondary market activity?
Caplight tracks bids, offers, and trades in GPN Vaccines's shares on secondary markets.